Completed
PHASE1
INTERVENTIONAL
NCT00474760
Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This is a phase 1 study of anti-IGF-IR CP-751,871 in patients with solid tumors currently enrolling patients 9 years old and older with Ewing's sarcoma family of tumors (Ewing's, PNET and Askin's).
Interventions
Name:
CP-751,871
Type:
DRUG
Description:
Currently dosing at 20 mg/kg, IV on day 1 of each 28 day cycle until progression or unacceptable toxicity
Primary Outcomes
Measure:
Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
TimeFrame:
Baseline up to 150 days after the last administration of study drug
Description:
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 150 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Trial Information
NCT ID
NCT00474760
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Pfizer
Last Updated
December 15, 2025